Allarity Therapeutics (ALLR) vs Marker Therapeutics (MRKR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed Allarity Therapeutics (ALLR) over the past year, losing 12.0% versus a loss of 42.2%. Marker Therapeutics is the larger company by market cap ($15.8 million vs $15.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | MRKR |
|---|---|---|
| Share price | $0.9819 | $0.95 |
| Market cap | $15.62M | $15.84M |
| 1-day change | -0.21% | -8.65% |
| YTD return | -9.08% | -36.24% |
| 1-year return | -42.24% | -12.04% |
| 5-year return | — | -94.03% |
| EPS (TTM) | $-0.79 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $2.46 |
| 52-week low | $0.769 | $0.84 |
| Distance from 52-week high | -46.64% | -61.38% |
| Analyst consensus | none | none |
| Avg. price target upside | +1020.28% | +728.42% |
| Average volume | 90.75K | 64.80K |
| Shares outstanding | 15.91M | 16.67M |
| Employees | 7 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed ALLR by 30.2 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Healthcare · Biotechnology · 7 employees
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Healthcare · Biotechnology · 5 employees
ALLR vs MRKR FAQ
Which is bigger, Allarity Therapeutics or Marker Therapeutics?
Marker Therapeutics (MRKR) is larger, with a market capitalization of $15.84M compared with $15.62M for Allarity Therapeutics (ALLR).
Which stock has performed better over the past year, ALLR or MRKR?
MRKR returned -12.04% over the past 12 months, compared with -42.24% for ALLR (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Marker Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.